Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07471503) titled 'Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Condition: Myelofibrosis (MF) HSCT

Intervention: Drug: Gecacitinib (also known as Jaktinib)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: March 16, 2026

Target Sample Size: 39

To know more, visit https://clinicaltrials.gov/study/NCT074715...